TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05500625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection
Description: Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ballon-occluded retrograde transvenous obliteration
Description: A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
Study: NCT04994106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
Study: NCT06438510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG)
Description: All endoscopic procedures will be performed with the patient in the supine position, under general anesthesia, with endotracheal intubation, in CO2 using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a dual-channel endoscope (GIF-2TH180 or GIF-2TH160; Olympus, Center Valley, PA, USA ). The HybridAPC with submucosal injection and APC will be delivered by ErbeJet®2. ESG will be obtained by placing full-thickness sutures in the body gastric wall, from the angulus to the gastric fundus. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. In the next step HybridAPC to the gastric mucosa of the fundus is applied.
Study: NCT05519540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant (Debio 1143)
Description: All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant (Debio 1143)
Description: All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
Study: NCT05857696

Intervention type: OTHER
Group type: OTHER
Intervention: walking quantified analysis
Description: Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.
Study: NCT05520554

Intervention type: OTHER
Intervention: Development of the Telerehabilitation Satisfaction Questionnaire
Description: This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
Study: NCT04375462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AspireAssist device
Description: Allows for aspiration of gastric contents into a receptacle or the toilet to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically in an identical fashion to a standard PEG tube G 1-2 days after enrollment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard decompressive PEG tube
Description: Allows for gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically 1-2 days after enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric outlet obstruction scoring system (GOOSS) questionnaire
Description: Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric outlet obstruction scoring system (GOOSS) questionnaire
Description: Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire
Description: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire
Description: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient satisfaction and ease of use survey
Description: Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient satisfaction and ease of use survey
Description: Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call
Study: NCT05989451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Description: The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
Study: NCT05048524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin and gemcitabine
Description: Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day
Study: NCT05412602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full spine corrective protocol
Description: 36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
Study: NCT05618691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312
Description: Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312
Description: Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312
Description: Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered to subjects in the placebo group
Study: NCT05910190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of buprenorphine with FAO > 30 OME
Description: Patients will receive buprenorphine with concurrent FAO \>30 OME and be assessed for withdrawal, pain, and other symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPM Rx application use
Description: The CPM Rx application is used on smart phones to allow patients to input time-stamped data about medication type, dosage, and pain score. This will allow analysis of trends in self-reported pain and optimal dosing patterns. Usage over three months will be assessed.
Study: NCT06134024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections
Description: During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only
Description: During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
Study: NCT06222788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Convertible Plasma Jet
Description: NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
Study: NCT04593264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-guided pre-habilitation exercise program
Description: A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pre-habilitation
Description: Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
Study: NCT06131060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive eccentric exercises
Description: This include progressive eccentric exercises thrice a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises
Description: This include bodyweight exercises thrice a week for 6 weeks
Study: NCT04497038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
Study: NCT04724824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface
Description: Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Brain-Computer Interface
Description: Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
Study: NCT04779788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)
Description: An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)
Description: Bare self-expanded metal stent
Study: NCT06492863

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.
Study: NCT05260684

Intervention type: DRUG
Intervention: Encorafenib
Description: 450 mg QD

Intervention type: DRUG
Intervention: Binimetinib
Description: 45 mg BID

Intervention type: DRUG
Intervention: Vemurafenib
Description: 960 mg BID for 28 days/cycle

Intervention type: DRUG
Intervention: Cobimetinib
Description: 60 mg QD for 21 days/cycle

Intervention type: DRUG
Intervention: Dabrafenib
Description: 150 mg BID

Intervention type: DRUG
Intervention: Trametinib
Description: 2 mg QD
Study: NCT05068882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Oral immunonutrition containing arginine, omega-PUFAs and antioxidants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-protein nutrition
Description: Oral nutrition with high-protein content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutrition
Description: Oral nutrition with standard ingredients
Study: NCT05865041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farudodstat
Description: Farudodstat tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farudodstat
Description: Farudodstat tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets administered orally
Study: NCT06519695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercises
Description: Performed exercise three times a week, one time at a community health service station and two times at home
Study: NCT04994106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo matched to AZD5462.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo matched to AZD5462.
Study: NCT06144099

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fresh frozen plasma
Description: transfusion of fresh frozen plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prothrombin complex concentrate
Description: prothrombin complex concentrate administration
Study: NCT04566887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Administered as 100mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP chemotherapy
Description: R-CHOP chemotherapy
Study: NCT06092281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Patients after ESD need to complete a questionnaire on compliance-related education before discharge. The questionnaire includes the following information:~1. General information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)~2. Awareness of follow-up examinations (e.g., knowledge about the timing of the first follow-up, the process of follow-up examinations, related educational issues about follow-up, etc.)~3. Awareness of the disease (self-perceived tumor is benign or malignant, whether lifestyle changes are required, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire without compliance-related education
Description: Patients after ESD need to complete a questionnaire without compliance-related education before discharge. The questionnaire includes only general information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)
Study: NCT00669123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate
Description: Chondroitin sulphate 800 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04617496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined speech and exercise intervention
Description: Home-based exercise intervention with interactive automated speech response features

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of topics
Study: NCT04997356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hostile Bias Modification Training
Description: Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hostile Bias Modification Training
Description: Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Other training
Description: Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Other training
Description: Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.
Study: NCT04872140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low phytate pea powder
Description: Exercise performance with low phytate pea powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular pea powder
Description: Exercise performance with regular pea powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: Exercise performance with placebo (maltodextrin)
Study: NCT04994106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo matched to AZD5462.
Study: NCT05563155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 24 mg
Description: Dexamethasone 24 mg on day 1 after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given on day 1 after surgery.
Study: NCT05246085

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortisol level
Description: Cortisol levels will be checked in both groups to screen for adrenal insufficiency.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortisol level
Description: Cortisol levels will be checked in both groups to screen for adrenal insufficiency.
Study: NCT04734561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training group
Description: Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training placebo group
Description: Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory + expiratory muscle training group
Description: Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory + expiratory muscle training placebo group
Description: Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
Study: NCT04756375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Use of virtual reality in the management of sickle cell patients with VOS

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual management of sickle cell patients with VOS